Long-Acting Injectable Cabotegravir for HIV Prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?

4 October 2022

This article from The Science of Prevention summarizes what is known about cabotegravir (CAB) pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and evaluates the risk of resistance from CAB for PrEP with on-time injections and after CAB for PrEP discontinuation.

Featured Resources

Document

Coordinating Implementation Science: Taking Stock of PrEP Evidence

This document summarises key takeaways from the BioPIC Think Tank held in March 2024 to review existing PrEP evidence and evidence gaps to date.

Document

Opportunities for Pharmacist-Delivered Injectable PrEP in the USA

These Quick Take briefings from Georgetown University’s O’Neill Institute for National and Global Health Law provide insights on barriers and opportunities for pharmacist-administered injectable PrEP in the USA, including delivery via mobile pharmacies.

Spreadsheet

MOSAIC – PrEP Site Implementation and New Product Readiness Assessment Tool

This tool is intended to provide insight into the current state of PrEP services and to identify critical barriers and facilitators to PrEP implementation. Additionally, this tool is designed to inform preparations for new PrEP product introduction (CAB PrEP, PrEP ring, or both) according to national priorities. Findings from readiness assessment visits using this tool…

Document

Private Sector Market Assessment: Eswatini

This market assessment explores the opportunities and barriers to leveraging private sector channels to expand access to new and existing pre-exposure prophylaxis (PrEP) methods, including oral PrEP, the dapivirine vaginal ring (PrEP ring), and long acting cabotegravir (CAB PrEP) in Eswatini.

Document

CAB PrEP Introduction Situation Analysis – Zimbabwe – 2023

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform. It aims to clarify critical steps for the introduction of biomedical HIV prevention products.

Document

CATALYST Interim Learnings (May-November 2023)

In this first interim analysis, the MOSAIC team provides key learnings from preparing for the delivery of PrEP choice, a summary of challenges experienced in implementing the enhanced service delivery model and the solutions introduced, programmatic considerations for countries preparing to introduce new PrEP methods, and a list of publicly accessible tools and resources used…

Document

Coordinating Implementation Science for CAB for PrEP: Early Insights from EBONI and PILLAR

This document summarises key takeaways from the BioPIC Think Tank on early insights from ViiV Healthcare’s two cabotegravir for PrEP implementation studies- EBONI and PILLAR.

Document

CAB PrEP Introduction Situation Analysis – Eswatini – 2023

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.

Document

CAB PrEP Introduction Situation Analysis – Kenya – 2023

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.

Document

CAB PrEP Compendium of End User Insights

Understanding end users is a critical first step to establishing effective communication and informing program delivery. This document intends to help inform development and updating of national HIV prevention, combination prevention, and PrEP communication and demand generation strategies, campaigns and plans with CAB-specific insights.** It can also be shared with program implementers to inform communication…